Indication
Chronic Delta Hepatitis
1 clinical trial
2 products
Product
lonafarnibProduct
RitonavirClinical trial
A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of a Titrating-Dose Lonafarnib/Ritonavir in Patients Chronically Infected With Hepatitis Delta VirusStatus: Completed, Estimated PCD: 2016-08-01